Determination of huperzine A in human plasma by liquid chromatography-electrospray tandem mass spectrometry: Application to a bioequivalence study on Chinese volunteers

Biomedical Chromatography

Volumn 22, Issue 4, 2008, Pages 354-360

  Li, Wei ^a   Li, Jianhua ^b   Hu, Qin ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Bioequivalence; Huperzine A; LC MS MS; Pharmacokinetics

Indexed keywords

ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN);

BIOEQUIVALENCE; BIOEQUIVALENCE STUDY; ELECTROSPRAY TANDEM MASS SPECTROMETRY; HUMAN PLASMAS; HUPERZINE A; LC-MS-MS; LC.MS/MS; LIQUID CHROMATOGRAPHY ELECTROSPRAY; PSEUDOEPHEDRINE HYDROCHLORIDES; SIMPLE++;

PHARMACOKINETICS;

ACETIC ACID ETHYL ESTER; CARBON; FORMIC ACID; HUPERZINE A; METHANOL; PSEUDOEPHEDRINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHINESE; CLINICAL TRIAL; COLUMN CHROMATOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER;

EID: 42549094991     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.938     Document Type: Article

References (12)

1. FDA. Guidance for Industry, Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001a; available at: http://www.fda.gov/cder/guidance/4252fnl.htm
2. FDA. Guidance for Industry, Statistical Approaches to Establishing Bioequivalence. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001b; available at: http://www.fda.gov/cder/guidance/index.htm
3. Li YX, Jiang XH, Lan K and Wang L. Simple determination of Huperzine A in human plasma by liquid chromatographic-tandem mass spectrometric method. Biomedical Chromatography 2007; 21: 15-20.
4. Liang YQ and Tang XC. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats. Neuroscience Letters 2004; 361: 56-59.
5. Qian BC, Wang M, Zhou ZF, Chen K, Zhou RR and Chen GS. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacologica Sinica 1995; 16: 396-398.
6. Wang R, Yan H and Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica 2006; 27: 1-26.
7. Wang T and Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. European Journal of Pharmacology 1998; 349: 137-142.
8. Xu SS, Gao ZX, Weng Z, Du ZM, Xu WA, Yang JS, Zhang ML, Tong ZH, Fang YS and Chai XS. Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacologica Sinica 1995; 16: 391-395.
9. Xu SS, Xie HB, Du ZM, Tong ZH, Shi QC, Lu KM, Li SL and Lin B. Efficacy of tablet huperzine A on memory and cognition in patients with benign senescent forgetfulness. Chinese Journal of Clinical Pharmacology and Therapeutics 1997; 2: 1-4.
10. Xu SS, Cai ZY, Qu ZW, Yang RM, Cai YL, Wang GQ, Su XQ, Zhong XS, Cheng RY, Xu WA, Li JX and Feng B. Huperzine A in capsules and tablets for treating patients with Alzheimer's disease. Acta Pharmacologica Sinica 1999; 20: 486-490.
11. Zhang ZX, Wang XD, Chen QT, Shu L, Wang JZ and Shan GL. Clinical efficacy and safety of huperzine alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, doubleblind, randomized trial. National Medical Journal of China 2002; 82: 941-944.
12. Zhao Q and Tang XC. Effects of huperzine A on acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. European Journal of Pharmacology 2002; 455: 101-107.